化疗联合半相合供者淋巴细胞输注治疗难治性非霍奇金淋巴瘤实验及临床研究

目的观察化学治疗联合有血缘关系HLA半相合淋巴细胞输注治疗难治性非霍奇金淋巴瘤的安全性和有效性。方法通过测定半相合供者淋巴细胞与患者淋巴瘤细胞共培养后淋巴瘤细胞的凋亡率，确定HLA半相合供体淋巴细胞体外抗淋巴瘤细胞的有效性。选取难治性非霍奇金淋巴瘤24例，在常规化疗后，输注有血缘关系HLA半相合淋巴细胞，对完成两个联合疗程的患者进行评价。结果淋巴瘤细胞培养过程中加入HLA半相合供体淋巴细胞可促进淋巴瘤细胞凋亡。24例共完成47个疗程的联合治疗，19例完成两个疗程以上，13例患者完全缓解，中位随访时间18个月，7例处于无病生存状态。半相合淋巴细胞输注后，低度发热5例，轻度皮肤潮红伴散在皮疹3例，对症处理后消失。结论常规化疗联合有血缘关系HLA半相合淋巴细胞输注治疗安全有效。

Experimental and clinical studies of treatment of refractory non-Hodgkin's lymphoma by chemotherapy combined with haploidentical donor's lymphocyte infusion

Objective To observe the saiety and eiticacy of chemotherapy combined with HLA - haploidentical donor ＇s lymphocyte infusion on refractory non - Hodgking lymphoma. Methods Through the measurement of the apoptosis rate of lymphoma cells eocuhured with HLA - haploidentical donorg lymphocytes, the anti - lymphoma effectiveness of HLA - haploidentical donor＇s lymphocytes was confirmed. 24 patients with refractory non - Hodgkin ＇s lymphoma were given conventional chemotherapy and infused HLA - haploidentical lymphocytes afterwards. The safety and side effects of this combined therapy were evaluated after 2 courses of treatment. Results Adding HLA - haploidentical donor＇s lymphocytes into the culture fluid containing lymphoma cells can promote the apoptosis of lymphoma cells. 24 patients received 47 courses of the combined therapy. Among them, 19 patients finished at least 2 courses of treatment, 13 patients achieved complete remission ;7 patients were in disease - free survival status at 18 months of median follow - up time after treatment. Following HLA - haploidentical lymphocyte infusion, 5 patients had low - grade fever and 3 patients had low degree of rubefaction with sporadic skin rashes. However, these symptoms disappeared after symptomatic treatment. Condusion Chemotherapy combined with HLA - haploidentical donor＇s lymphocyte infusion is safe and effective to treat refractory non - Hodgking lymphoma.